Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time
Regulatoryrejectedrivoceranibcombination therapyNegative
AI Analysis
Summary
The FDA rejected a combination therapy filing from Hengrui and Elevar for the third time, citing manufacturing deficiencies discovered during inspection of the facility producing rivoceranib. This repeated rejection represents a significant regulatory setback for the partnered development program.
Outcome Details
FDA rejected filing for combination therapy including rivoceranib due to manufacturing deficiencies uncovered during facility inspection. This is the third rejection for the partners.
Importance:8/10
Sentiment:
-0.95
FDA rejectionmanufacturing deficiencyHengruiElevarrivoceranibregulatory setback
Read the original article
Published by BioSpace on July 15, 2026 11:47 AM